It´s onsite, 09 - 11 September 2025
Vilnius, Lithuania.

Program www.escmid-foundation.org/fileadmin/es...

www.esmycobacteriology.eu/event-home

Also in DK, we need strong support networks and health systems that reach the vulnerable groups where they are. Let’s not wait for the numbers to rise like in UK but but focus on targeted prevention to stay ahead of the curve.

TB continues to disproportionately affect the most vulnerable. E.g. people experiencing homelessness, migration and socio-economic instability. They are at higher risk of infection and face barriers that complicate access to diagnosis and completion of treatment.

The BMJ editorial underscores the need for pronged action, stronger healthcare support, and targeted interventions, especially for vulnerable groups.
In Denmark, we don´t see the same general increase in TB incidence. However, we see similar patterns within specific high-risk groups

Venn diagram of the fulfilment of diagnostic guideline criteria for NTM pulmonary disease (n=184, 9 patients did not fulfil any component of the criteria)

N=193. MAC (56%), gordonae (15%), xenopi (11%) most common. Cough (62%), expectoration (51%), dyspnea (43%), and systemic symp. (42%), with 36% symptoms for > 6 mths. Median time first hospital contact to first NTM sample 14 days. 45% ptt. seen in a fast-track pulmonary cancer referral pathway.

Yes, but they often include B, L (or D also difficult to get). I understood your initial question/comment as what to do if BPaL not available.
BW

I am not involved in the study but just found it interesting. Do you mean what should be used if you don´t have access to BPaL but do have fluoroquinolones? That would indeed be a longer (difficult) individualized regimen